We are live on ! Find out more
FBIOP icon

Fortress Biotech 9.375% Series A Preferred Stock
FBIOP

3 hedge funds and large institutions have $5.26M invested in Fortress Biotech 9.375% Series A Preferred Stock in 2020 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 1

46% more capital invested

Capital invested by funds: $3.61M → $5.26M (+$1.65M)

0% more funds holding

Funds holding: 3 → 3 (0)

0.67% less ownership

Funds ownership: 11.59% → 10.91% (-0.67%)

Holders
3
Holders Change
–
Holders Change %
0%
% of All Funds
0.06%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
2
Reduced
1
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
UIC
Uniplan Investment Counsel
Wisconsin
+$1.03M
2
PCG
Private Capital Group
Connecticut
+$1.13K

Top Sellers

Rank Fund Capital Flow
1
SAM
Shikiar Asset Management
New York
-$18.1K
Name Holding Trade Value Shares
Change 		Change in
Stake
UIC
1
Uniplan Investment Counsel
Wisconsin
$3.79M +$1.03M +56,960 +37%
SAM
2
Shikiar Asset Management
New York
$1.47M -$18.1K -1,000 -1%
PCG
3
Private Capital Group
Connecticut
$2K +$1.13K +62 +85%

FBIOP Hedge Fund Activity: Q2 2020 in Review

3 of the 4,878 institutional investors tracked by Wall St. Rank reported a position in Fortress Biotech 9.375% Series A Preferred Stock (FBIOP) for Q2 2020, worth a combined $5.26M — up 46% from $3.61M a quarter earlier.

Fund positioning in FBIOP was balanced in Q2 2020: 0 funds opened new positions, 0 closed out, 2 added to existing stakes and 1 trimmed.

The largest buyer was Uniplan Investment Counsel, adding an estimated $1.03M. The largest seller was Shikiar Asset Management, cutting an estimated $18.1K.

  • 3 institutional investors held Fortress Biotech 9.375% Series A Preferred Stock (FBIOP) as of Q2 2020, unchanged from Q1 2020.
  • Funds reported $5.26M of Fortress Biotech 9.375% Series A Preferred Stock stock for Q2 2020, up 46% quarter-over-quarter.
  • 0 funds opened new Fortress Biotech 9.375% Series A Preferred Stock positions in Q2 2020 and 0 closed out.
  • The largest Fortress Biotech 9.375% Series A Preferred Stock buyer in Q2 2020 was Uniplan Investment Counsel, an estimated $1.03M added.
  • The largest Fortress Biotech 9.375% Series A Preferred Stock seller in Q2 2020 was Shikiar Asset Management, an estimated $18.1K sold.

Based on aggregated 13F filings for Q2 2020.